Star Combo Pharma (ASX:S66) Growth Rank: 0 (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:S66 Star Combo Pharma Ltd ASX:S66
19 GF Score
Price A$0.14
GF Value A$0.13
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Star Combo Pharma Growth Rank?

Star Combo Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Star Combo Pharma Growth Rank Related Terms

ASX:S66
19GF Score
Star Combo Pharma Ltd ASX:S66
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Star Combo Pharma (ASX:S66) Overvalued in 2026?

Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued. The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13. GuruFocus considers Star Combo Pharma to be Fairly Valued.

Key valuation signals for ASX:S66:

  • Growth Rank: 0
  • GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
  • GF Score™: 19/100 with 4 warning signs

No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Combo Pharma Business Description

Address 171 - 177 Woodpark Road, Smithfield, Sydney, NSW, AUS, 2164
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
19GF Score

Get the complete analysis for ASX:S66

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14
Price
A$0.13
GF Value